chr3-37001024-A-G
Variant summary
Our verdict is Uncertain significance. Variant got 1 ACMG points: 2P and 1B. PM1BP4
The ENST00000231790.8(MLH1):āc.277A>Gā(p.Ser93Gly) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000646 in 1,611,026 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. S93N) has been classified as Uncertain significance.
Frequency
Consequence
ENST00000231790.8 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 1 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
MLH1 | NM_000249.4 | c.277A>G | p.Ser93Gly | missense_variant | 3/19 | ENST00000231790.8 | NP_000240.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
MLH1 | ENST00000231790.8 | c.277A>G | p.Ser93Gly | missense_variant | 3/19 | 1 | NM_000249.4 | ENSP00000231790 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0000657 AC: 10AN: 152224Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000159 AC: 4AN: 251392Hom.: 0 AF XY: 0.0000221 AC XY: 3AN XY: 135876
GnomAD4 exome AF: 0.0000644 AC: 94AN: 1458802Hom.: 0 Cov.: 29 AF XY: 0.0000730 AC XY: 53AN XY: 726016
GnomAD4 genome AF: 0.0000657 AC: 10AN: 152224Hom.: 0 Cov.: 32 AF XY: 0.0000672 AC XY: 5AN XY: 74372
ClinVar
Submissions by phenotype
not provided Uncertain:3Benign:3
Uncertain significance, no assertion criteria provided | clinical testing | Laboratory of Diagnostic Genome Analysis, Leiden University Medical Center (LUMC) | - | - - |
Uncertain significance, no assertion criteria provided | clinical testing | Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen | - | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Nov 01, 2024 | MLH1: PM2 - |
Likely benign, no assertion criteria provided | clinical testing | Department of Pathology and Laboratory Medicine, Sinai Health System | - | The MLH1 p.Ser93Gly variant was identified in 16 of 2132 proband chromosomes (frequency: 0.007) from individuals or families with Lynch syndrome (Barnetson 2008, Jansen 2016, van Puijenbroek 2008, Raevaara 2005). The variant was also identified in dbSNP (ID: rs41295282 as "With Uncertain significance allele"), ClinVar (1x as benign by Invitae; 3x as likely benign by GeneDx, Ambry Genetics, and Mayo Clinic; and 2x as uncertain significance by InSiGHT and Counsyl), MutDB, UMD-LSDB (1x as unclassified variant), Mismatch Repair Genes Variant Database, and Insight Hereditary Tumors database (37x). The variant was not identified in the Gene Insight-COGR, Cosmic, or Zhejiang University databases. The variant was identified in control databases in 6 of 277126 chromosomes at a frequency of 0.00002 (Genome Aggregation Database Feb 27, 2017). The variant was observed in the following populations: African in 1 of 24028 chromosomes (freq: 0.00004), European in 4 of 126634 chromosomes (freq: 0.00003), and South Asian in 1 of 30780 chromosomes (freq: 0.00003), while the variant was not observed in the Other, Latino, Ashkenazi Jewish, East Asian, or Finnish populations. In addition, several functional studies using in vitro Mismatch Repair Assays identify the variant has normal MMR activity (Andersen 2012, Drost 2010, Kansikas 2011, Ou 2007, Takahashi 2007, Thompson 2013, Wanat 2007, Raevaara 2005). However, the variant exhibited reduction of protein efficiency compared to the wild-type, suggesting this may be a low penetrance variant (Vogelsang 2009). The p.Ser93 residue is conserved in mammals but not in more distantly related organisms; however, 4 of 5 computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM, MutationTaster) do not suggest a high likelihood of impact to the protein; this information is not predictive enough to rule out pathogenicity. The variant occurs outside of the splicing consensus sequence and 3 of 5 in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer, HumanSpliceFinder) predict a greater than 10% difference in splicing. However, this information is not predictive enough to assume pathogenicity. In addition, analysis using the pCAS reporter assay showed splice patterns of the variant allele were the same as the wild type (van der Klift 2015). In summary, based on the above information, the clinical significance of this variant cannot be determined with certainty at this time although we would lean towards a more benign role for this variant. This variant is classified as likely benign. - |
Likely benign, criteria provided, single submitter | clinical testing | Quest Diagnostics Nichols Institute San Juan Capistrano | Aug 11, 2021 | - - |
Likely benign, criteria provided, single submitter | clinical testing | GeneDx | Mar 30, 2021 | This variant is associated with the following publications: (PMID: 10671064, 11793442, 27300758, 28932927, 11555625, 22753075, 26247049, 16083711, 22949387, 12547705, 14871975, 18415027, 18033691, 17510385, 17210669, 19863800, 20020535, 12513688, 17594722, 21120944, 29575718, 32081490) - |
Hereditary cancer-predisposing syndrome Benign:3
Likely benign, criteria provided, single submitter | curation | Sema4, Sema4 | Sep 18, 2021 | - - |
Likely benign, criteria provided, single submitter | clinical testing | Color Diagnostics, LLC DBA Color Health | Sep 11, 2023 | - - |
Likely benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Mar 05, 2019 | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
Colorectal cancer, hereditary nonpolyposis, type 2 Uncertain:1Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Myriad Genetics, Inc. | Dec 12, 2023 | This variant is considered likely benign. This variant is strongly associated with less severe personal and family histories of cancer, typical for individuals without pathogenic variants in this gene [PMID: 27363726]. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Counsyl | Dec 08, 2015 | - - |
not specified Benign:2
Likely benign, no assertion criteria provided | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | - | - - |
Likely benign, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jun 06, 2022 | Variant summary: MLH1 c.277A>G (p.Ser93Gly) results in a non-conservative amino acid change located in the DNA mismatch repair protein family, N-terminal and Histidine kinase/HSP90-like ATPase domains of the encoded protein sequence. Three of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 1.6e-05 in 251392 control chromosomes (gnomAD). The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. c.277A>G has been reported in the literature in affected individuals (Schneider_2018, Jansen_2016, Barnetson _2008, Hendriks _2003, Nystrom-Lahti_2002, Quaresima _1998). These reports do not provide unequivocal conclusions about association of the variant with Lynch Syndrome. Jansen_2016 reports a patient that carried the variant of interest along with another pathogenic germline MUTYH variant, c1187G>A (p.G396D) and a somatic MLH1 variant, c.281delT (p.(S95LfsX13), providing supporting evidence for a benign role. Several functional studies have been performed to assess the variant's impact on interaction and binding with PMS2 and Exo1, MMR activity, nuclear localization and expression, and splice pattern (Andersen_2012, Drost_2010, Takahashi_2007, Wanat_2007, Raevaara_2005, Nystrom-Lahti_2002, Ellison_2001). Thru these studies, the variant of interest was found to perform comparably to wild-type function. Six ClinVar submissions from clinical diagnostic laboratories (evaluation after 2014) cite the variant as benign (n=1), likely benign (n=3) and uncertain significance (n=1). Based on the evidence outlined above, the variant was classified as likely benign. - |
Breast and/or ovarian cancer Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | CHEO Genetics Diagnostic Laboratory, Children's Hospital of Eastern Ontario | Feb 14, 2022 | - - |
Hereditary nonpolyposis colorectal neoplasms Benign:1
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 30, 2024 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at